[go: up one dir, main page]

WO2006063048A3 - Ibudilast for treating neuropathic pain and associated syndromes - Google Patents

Ibudilast for treating neuropathic pain and associated syndromes Download PDF

Info

Publication number
WO2006063048A3
WO2006063048A3 PCT/US2005/044258 US2005044258W WO2006063048A3 WO 2006063048 A3 WO2006063048 A3 WO 2006063048A3 US 2005044258 W US2005044258 W US 2005044258W WO 2006063048 A3 WO2006063048 A3 WO 2006063048A3
Authority
WO
WIPO (PCT)
Prior art keywords
ibudilast
neuropathic pain
treating neuropathic
associated syndromes
syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/044258
Other languages
French (fr)
Other versions
WO2006063048A2 (en
Inventor
Kirk W Johnson
Lance Sulzbaugh
Jennifer Shumilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avigen Inc
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Priority to BRPI0518829-6A priority Critical patent/BRPI0518829A2/en
Priority to EP05853230A priority patent/EP1835913A2/en
Priority to MX2007006777A priority patent/MX2007006777A/en
Priority to AU2005314133A priority patent/AU2005314133B2/en
Priority to JP2007544628A priority patent/JP4954085B2/en
Priority to CA2587791A priority patent/CA2587791C/en
Publication of WO2006063048A2 publication Critical patent/WO2006063048A2/en
Publication of WO2006063048A3 publication Critical patent/WO2006063048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of ibudilast for treating neuropathic pain.
PCT/US2005/044258 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes Ceased WO2006063048A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0518829-6A BRPI0518829A2 (en) 2004-12-06 2005-12-06 Method for the treatment of neuropathic pain and associated syndromes
EP05853230A EP1835913A2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes
MX2007006777A MX2007006777A (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes.
AU2005314133A AU2005314133B2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes
JP2007544628A JP4954085B2 (en) 2004-12-06 2005-12-06 Ibudilast for the treatment of neuropathic pain and its associated symptoms
CA2587791A CA2587791C (en) 2004-12-06 2005-12-06 Method for treating neuropathic pain and associated syndromes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63424804P 2004-12-06 2004-12-06
US60/634,248 2004-12-06
US66527605P 2005-03-25 2005-03-25
US60/665,276 2005-03-25
US71633305P 2005-09-12 2005-09-12
US60/716,333 2005-09-12

Publications (2)

Publication Number Publication Date
WO2006063048A2 WO2006063048A2 (en) 2006-06-15
WO2006063048A3 true WO2006063048A3 (en) 2006-08-24

Family

ID=36476178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044258 Ceased WO2006063048A2 (en) 2004-12-06 2005-12-06 Ibudilast for treating neuropathic pain and associated syndromes

Country Status (8)

Country Link
US (2) US7534806B2 (en)
EP (1) EP1835913A2 (en)
JP (2) JP4954085B2 (en)
AU (1) AU2005314133B2 (en)
BR (1) BRPI0518829A2 (en)
CA (1) CA2587791C (en)
MX (1) MX2007006777A (en)
WO (1) WO2006063048A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008116720A (en) * 2005-09-26 2009-11-10 Эвиджен, Инк. (Us) WAYS OF TREATMENT OF DRUG ADDICTION AND ADDICTIVE HABITS IN BEHAVIOR
US20070191365A1 (en) * 2006-01-13 2007-08-16 Lance Sultzbaugh 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes
CA2654498A1 (en) * 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
WO2008057496A2 (en) * 2006-11-09 2008-05-15 Avigen, Inc. Method for treating delirium
DK2131841T3 (en) * 2007-01-30 2012-10-15 Avigen Inc Methods for treating acute pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
JP5468001B2 (en) 2007-07-11 2014-04-09 メディシノバ，インコーポレーテッド Pharmaceutical composition for the treatment of progressive neurodegenerative diseases comprising ibudilast
US20090028816A1 (en) * 2007-07-27 2009-01-29 Lance Sultzbaugh Treatment of depression, psychosis, and anxiety
EP2558101A4 (en) * 2010-04-15 2013-09-18 Univ Mcgill TOPICAL PAIN TREATMENTS
RU2459642C2 (en) * 2010-04-27 2012-08-27 Министерство обороны Российской Федерации, Государственное образовательное учреждение высшего профессионального образования Военно-медицинская академия им. С.М. Кирова (ВМедА) Method of treating traumatic neuropathies
HUE039328T2 (en) * 2010-08-04 2018-12-28 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EP2701700A4 (en) * 2011-04-27 2015-10-21 Univ Yale Inc PHARMACEUTICAL THERAPY FOR INHIBITING CHEMOTHERAPY-INDUCED SIDE EFFECTS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHOD AND KITS
CN107206097A (en) * 2014-11-18 2017-09-26 皮克萨尔比奥公司 For treating acute, postoperative or chronic ache composition and its application method
JP6827924B2 (en) 2014-11-26 2021-02-10 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． Pharmaceuticals and compositions comprising a combination of ibudilast and riluzole
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US20180147141A1 (en) * 2016-11-29 2018-05-31 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
JP2020504721A (en) 2016-12-22 2020-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． Method for treating glioblastoma multiforme using ibudilast
WO2019157428A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
EP3752147A4 (en) 2018-02-12 2021-10-20 MediciNova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
US10946071B2 (en) 2018-10-09 2021-03-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
CN112804999B (en) 2018-10-19 2024-03-15 美迪诺亚公司 Treatment of Ophthalmic Disease/Condition or Injury with Ibudilast
US12377074B2 (en) * 2019-06-11 2025-08-05 Yale University Treatment for Wolfram syndrome
EP4034090A1 (en) 2019-09-23 2022-08-03 MediciNova, Inc. Ibudilast oral formulations and methods of using same
US12213966B2 (en) 2020-04-06 2025-02-04 Medicinova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients
JP2024506840A (en) * 2021-01-29 2024-02-15 メディシノバ・インコーポレイテッド How to treat chemical gas exposure
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US20230090534A1 (en) 2021-09-21 2023-03-23 Medicinova, Inc. Methods of treating glioblastoma multiforme using combination therapy
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
US12171752B2 (en) 2022-02-01 2024-12-24 Medicinova, Inc. Methods of treating post-COVID condition(s)
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263520A (en) 1985-09-14 1987-03-20 Kyorin Pharmaceut Co Ltd antirheumatic agent
US6136839A (en) 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000009127A1 (en) * 1998-08-10 2000-02-24 Kyorin Pharmaceutical Co., Ltd. Remedies for multiple sclerosis
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US7135495B2 (en) 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
AU2001257591A1 (en) 2000-03-31 2001-10-15 Biogen, Inc. Methods of identifying integrin ligands using differential gene expression
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2002022556A1 (en) 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
WO2002045750A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Combination drugs
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002098429A1 (en) 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
WO2003011289A1 (en) * 2001-07-31 2003-02-13 Pharmacia + Upjohn Company Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
WO2003013513A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Stable emulsion composition
CA2456754A1 (en) 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
EP1415983A4 (en) 2001-08-09 2006-01-18 Kissei Pharmaceutical 5-amidino-n-(2-aminophenethyl)-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co Indole derivatives
JP4292402B2 (en) 2001-09-07 2009-07-08 小野薬品工業株式会社 Indole derivative compounds, methods for producing them, and agents containing them as active ingredients
EP1443041A4 (en) 2001-11-09 2006-06-07 Kissei Pharmaceutical 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CN1653046A (en) 2002-03-05 2005-08-10 小野药品工业株式会社 8-Azaprostaglandin derivative compound and medicine containing the compound as an active ingredient
AU2003235097A1 (en) 2002-04-24 2003-11-10 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
US7125888B2 (en) 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc Kinase inhibitors
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20060083714A1 (en) 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
CA2518506A1 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
CL2004000545A1 (en) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B USE OF AN ANTAGONIST OF ALDOSTERONE RECEPTORS AND AN ENDOTHELINE RECEIVER ANTAGONIST FOR THE TREATMENT OR PROFILAXIS OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATHY AND CARDIOVASCUL DISEASES
CL2004000544A1 (en) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B USE OF A PHARMACEUTICAL COMBINATION, OF AN ALGOSTERONE RECEIVER ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR, USEFUL FOR THE TREATMENT AND PREVENTION OF A PATHOLOGICAL CONDITION RELATED TO HYPERTENSION, RENAL DYSFUNCTION, INSULINOPATI
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CN1905870A (en) 2003-11-21 2007-01-31 康宾纳特克斯公司 Methods and reagents for treating inflammatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARK H: "The effects of ibudilast on diabetic peripheral neuropathy (2)", JAPANESE PHARMACOLOGY AND THERAPEUTICS 1995 JAPAN, vol. 23, no. 6, 1995, pages 133 - 140, XP009067303, ISSN: 0386-3603 *

Also Published As

Publication number Publication date
JP4954085B2 (en) 2012-06-13
US20060160843A1 (en) 2006-07-20
AU2005314133A1 (en) 2006-06-15
JP2008522979A (en) 2008-07-03
JP2008013577A (en) 2008-01-24
MX2007006777A (en) 2007-08-06
US20090209575A1 (en) 2009-08-20
WO2006063048A2 (en) 2006-06-15
EP1835913A2 (en) 2007-09-26
CA2587791A1 (en) 2006-06-15
AU2005314133B2 (en) 2012-03-08
US7534806B2 (en) 2009-05-19
BRPI0518829A2 (en) 2008-12-09
CA2587791C (en) 2012-03-13

Similar Documents

Publication Publication Date Title
WO2006063048A3 (en) Ibudilast for treating neuropathic pain and associated syndromes
IL185485A0 (en) Use of pde7 inhibitors for the treatment of neuropathic pain
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2007020103A3 (en) Novel use of peptide compounds for treating muscle pain
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1727530A4 (en) Topical formulations for the treatment of skin conditions
IL201309A0 (en) Novel n - (8 - heteroaryltetrahydronaphtalene - 2yl) or n - (5 - heteroarylchromane - 3 - yl) carboxamide derivatives for the treatment of pain
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2007121125A3 (en) Hcv inhibitors
IL182993A0 (en) Treatment of mastitis
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
EP1814567A4 (en) Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
EP1885351A4 (en) Methods and compositions for the treatment of pain
ZA200707147B (en) Use of PDE7 inhibitors for the treatment of neuropathic pain
WO2008089494A3 (en) Methods of use of epsilon inhibitor compounds for the attenuation of pain
WO2008124698A3 (en) Methods of use of gamma inhibitor compounds for the attenuation of pain
GB0330049D0 (en) The treatment of neuropathic pain conditions
AP2007003982A0 (en) Use of androgens to reduce the likelihood of acquring or to treat skin aging
WO2005023253A8 (en) Use of pde4 inhibitors for the treatment of diabetes mellitus
WO2006095173A3 (en) Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0408521D0 (en) Treatment of sepsis
WO2006010077A3 (en) Prodrugs of lonidamine and lonidamine analogs
WO2006081272A3 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2587791

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005314133

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 555312

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007544628

Country of ref document: JP

Ref document number: 2005853230

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006777

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2005314133

Country of ref document: AU

Date of ref document: 20051206

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005314133

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007125465

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005853230

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0518829

Country of ref document: BR